Brain Tumor Vaccine Fast-Tracked: FDA approves or grants breakthrough status within 60 days

58%

probability · 58% confidence · 60 days

Deutsche Welle reported a new brain tumor vaccine offering patients 'hope for more time,' signaling clinical momentum. Glioblastoma remains uniformly fatal with median survival ~15 months. Fast-track or breakthrough designation often follows early efficacy signals and can arrive before full Phase 3 completion, especially for unmet-need cancers. FDA has accelerated oncology decisions post-2020; 30-60 day windows for designation decisions are historically plausible when safety/efficacy bars are met in Phase 2b trials.

Brunu publishes AI-generated probability forecasts on world events, markets, and policy. Forecasts update as new signals come in and are graded correct/incorrect at close — full track record at brunu.ai/forecasts. Informational only. Not financial, legal, or medical advice.